Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal. 

The European Commission thinks that CBD might be a narcotic, after all. What should companies be doing while it decides? In this exclusive interview, regulatory expert Greer Deal – director at Global Regulatory Services – suggests that companies that haven’t already done so should consider filing Novel Food (NF) applications with both the European Commission and the UK Food Standards Agency.

Leaning towards classifying CBD as a narcotic, the European Commission could dash hopes of a regulated EU market for dietary supplements containing the cannabinoid.